Results 91 to 100 of about 539,919 (309)

Large‐cohort humanized NPI mice reconstituted with CD34 ⁺ hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy [PDF]

, 2022
XiongFei Xu, Haihui Gu, Hongwei Li, Suizhi Gao, Xiaohan Shi, Jing Shen, Bo Li, Huan Wang, Kailian Zheng, Zhuo Shao, Peng Cheng, Zhanshan Cha, Siying Peng, Yongzhan Nie, Zhao-Shen Li, Shiwei Guo, Baohua Qian, Gang Jin, XiongFei Xu, Haihui Gu, Hongwei Li, Suizhi Gao, Xiaohan Shi, Jing Shen, Bo Li, Huan Wang, Kailian Zheng, Zhuo Shao, Peng Cheng, Zhanshan Cha, Siying Peng, Yongzhan Nie, Zhao-Shen Li, Shiwei Guo, Baohua Qian, Gang Jin   +35 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Characteristics and clinical significance of immune cells in omental milky spots of patients with gastric cancer

Frontiers in Immunology
The omentum is a common site of peritoneal metastasis in various cancers, including gastric cancer. It contains immune cell aggregates known as milky spots, which provide a microenvironment for peritoneal immunity by regulating innate and adaptive immune
Yasunobu Mano, Yasunobu Mano, Yuka Igarashi, Yuka Igarashi, Keisuke Komori, Keisuke Komori, Itaru Hashimoto, Itaru Hashimoto, Hayato Watanabe, Kosuke Takahashi, Kazuki Kano, Hirohito Fujikawa, Takanobu Yamada, Hidetomo Himuro, Hidetomo Himuro, Taku Kouro, Taku Kouro, Feifei Wei, Feifei Wei, Kayoko Tsuji, Kayoko Tsuji, Shun Horaguchi, Shun Horaguchi, Shun Horaguchi, Mitsuru Komahashi, Mitsuru Komahashi, Mitsuru Komahashi, Takashi Oshima, Tetsuro Sasada, Tetsuro Sasada   +29 more
doaj   +1 more source

Moving forward to address key unanswered questions on targeting PD-1/PD-L1 in cancer: limitations in preclinical models and the need to incorporate human modifying factors. [PDF]

, 2019
The tremendous clinical success of immune checkpoint inhibition (ICI), particularly targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1/2 (PD-L1/2) pathway, has resulted in application to multiple cancers, as a monotherapy and ...
Le, Catherine T, Murphy, William J
core   +1 more source

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers. [PDF]

, 2020
PurposeStudies have demonstrated an association between quantity of circulating tumor DNA (ctDNA) and poorer survival. We investigated the relationship between percent ctDNA (%ctDNA), total number of ctDNA alterations, and overall survival (OS) in liquid
Goodman, Aaron, Khagi, Yulian, Kurzrock, Razelle, Riviere, Paul, Vu, Peter   +4 more
core  

Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer

, 2021
Mirte Muller, Roland Hoogendoorn, Ruben Moritz, Vincent van der Noort, Mirthe Lanfermeijer, Catharina M. Korse, Daan van den Broek, Jelle J. ten Hoeve, Paul Baas, Huub H. van Rossum, Michel M. van den Heuvel   +10 more
openalex   +2 more sources

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy

Journal of Immunology Research, 2020
Until now, three types of well-recognized cancer treatments have been developed, i.e., surgery, chemotherapy, and radiotherapy; these either remove or directly attack the cancer cells. These treatments can cure cancer at earlier stages but are frequently
Yuka Igarashi, Tetsuro Sasada
doaj   +1 more source

Immune targets in the tumor microenvironment treated by radiotherapy. [PDF]

, 2019
Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagnosis, has the advantage of local tumor control with relatively less systematic side effects comparing to chemotherapy.
Li, Jian Jian, Ozpiskin, Omer M, Zhang, Lu   +2 more
core